KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Cardlytics (CDLX) Cost of Revenue (2017 - 2026)

Cardlytics filings provide 10 years of Cost of Revenue readings, the most recent being $6.8 million for Q1 2026.

  • Quarterly Cost of Revenue fell 34.88% to $6.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $33.5 million through Mar 2026, down 31.54% year-over-year, with the annual reading at $39.5 million for FY2025, 25.02% down from the prior year.
  • Cost of Revenue hit $6.8 million in Q1 2026 for Cardlytics, down from $7.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $22.0 million in Q2 2022 and bottomed at $6.8 million in Q1 2026.
  • Average Cost of Revenue over 5 years is $13.5 million, with a median of $14.0 million recorded in 2024.
  • The largest annual shift saw Cost of Revenue surged 33.68% in 2022 before it tumbled 40.25% in 2025.
  • Cardlytics' Cost of Revenue stood at $16.8 million in 2022, then dropped by 16.13% to $14.1 million in 2023, then fell by 19.62% to $11.3 million in 2024, then tumbled by 33.67% to $7.5 million in 2025, then fell by 10.14% to $6.8 million in 2026.
  • Per Business Quant, the three most recent readings for CDLX's Cost of Revenue are $6.8 million (Q1 2026), $7.5 million (Q4 2025), and $7.9 million (Q3 2025).